Citigroup Cuts ALNY Price Target to $320
Citigroup has reiterated its Buy rating on Alnylam Pharmaceuticals and lowered its price target to $320, a 37.21% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Citigroup cut its price target on Alnylam Pharmaceuticals, Inc. ($ALNY) to $320 from $340 on October 14, 2026, and rates the stock "Buy".
Since the rating, $ALNY is up 3.3% to date (from the $224.47 close on Oct 14, 2026).
ALNY
Alnylam Pharmaceuticals, Inc.
Key Points
- On October 14, 2026, Citigroup reiterated its Buy rating on Alnylam Pharmaceuticals with a new price target of $320, down from $340.
- Citigroup's $320 price target implies 37.21% upside from Alnylam Pharmaceuticals, Inc.'s ($ALNY) current $233.22 share price.
- As of October 16, 2026, Alnylam shares were recently trading at $233.22, which is 27.1% below Citigroup's new price target.
- Alnylam is expected to report earnings on October 29, 2026, following a year of revenue growth of 66.9%.
Get $ALNY trade alerts by text
We text you when insiders, Congress or big funds trade $ALNY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Alnylam Pharmaceuticals, Inc. alert may contain errors. Disclosures
Citigroup has reiterated its Buy rating on Alnylam Pharmaceuticals, Inc. (ALNY) on October 14, 2026, and lowered its price target to $320 from $340. This change reflects the firm's ongoing confidence in the company despite the adjustment.
The recent share price of Alnylam is $233.22, which is 27.1% below Citigroup's new target. This gap suggests potential for growth if the stock can align more closely with the target in the future.
Other Institutional Activity in Alnylam Pharmaceuticals
Several other institutional investors have also shown interest in Alnylam. FMR, LLC holds about 15,023,962 shares worth approximately $3.48 billion after adding 444,668 shares. Capital World Investors owns 11,144,846 shares valued at about $2.58 billion, increasing its stake by 342,436 shares. Blackrock Inc. has 10,907,675 shares worth around $2.53 billion after a 462,712 share increase. Additionally, Capital Research Global Investors holds 9,750,699 shares valued at about $2.26 billion, with a 279,403 share increase. Vanguard Portfolio Management LLC has a smaller stake of 6,538,390 shares worth about $1.52 billion, with a slight increase of 47,384 shares.
Alnylam Pharmaceuticals, Inc. Stock Down 2.6%
Alnylam shares are currently trading below Citigroup's revised price target, which could indicate an opportunity for investors if the stock rebounds. The shares have been volatile, with recent trading suggesting a disconnect between market perception and analyst expectations.
$ALNY price target
Alnylam Pharmaceuticals, Inc. daily closes and this analyst's $320 target. Not advice.
Recent Earnings
Alnylam reported a trailing twelve-month revenue of approximately $4.80 billion and an EPS of $5.75. The company has demonstrated significant growth, with a year-over-year revenue growth rate of 66.9% and a net margin of 16.1%. The next earnings report is scheduled for October 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 56.5%. Revenue beat estimates by 2.7%.
-
Profit surprise
EBITDA missed by 5 percent. Operating income beat by 55 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin down 6.1 points. Operating margin up 20.0 points. Negative free cash flow.
Earnings Call Summary
Alnylam delivered 1.17 billion dollars in total product revenue in the first quarter, marking its first quarter exceeding 1 billion dollars. The TTR franchise generated 910 million dollars, up 153 percent year over year, with U.S. revenue growing 230 percent driven by strong AMVUTTRA adoption for heart disease. Management highlighted over 90 percent patient adherence to vutrisiran and broader international success including new launches in Europe and Japan, though Germany pricing adjustments created a temporary headwind that they expect to reverse in coming quarters.
Guidance Management reaffirmed full year guidance of 4.4 to 4.7 billion dollars in TTR revenue, expecting significantly higher quarter-over-quarter growth for the rest of 2026. They also expect the rare disease portfolio to continue contributing steady growth alongside the TTR cardiomyopathy launch expansion in international markets.
Negative report. Results or guidance disappointed and expectations are likely to move lower.
Insider Buying and Selling at Alnylam Pharmaceuticals, Inc.
Recent insider transactions include several sales by officers and directors. Kevin Joseph Fitzgerald sold 1,291 shares on March 5, 2026, valued at approximately $417,685. On April 6, 2026, Melissa Mclaughlin sold 3,910 shares for around $1.27 million. David E I Pyott sold 3,830 shares on June 1, 2026, valued at about $1.15 million. Most recently, Bryan Supran sold 1,758 shares on October 2, 2026, at an average price of $226.88, totaling about $398,855.
Analysts Set New Price Targets
On October 14, 2026, Citigroup maintained its Buy rating on Alnylam Pharmaceuticals with a new price target of $320, down from $340. Earlier, on October 8, 2026, RBC Capital maintained its Outperform rating with a target of $345, decreased from $350. On September 30, 2026, JP Morgan maintained an Overweight rating with a target of $369, down from $375. HC Wainwright & Co. reiterated a Buy rating with a target of $455 on September 21, 2026. The consensus among analysts suggests continued optimism for Alnylam's future performance.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, located in Cambridge, MA, focuses on developing therapies based on ribonucleic acid interference. The company offers several treatments, including ONPATTRO for hereditary transthyretin-mediated amyloidosis and AMVUTTRA for various amyloidosis types. Its innovative approach positions it as a key player in the biotechnology sector.
Bottom Line
Investors should keep an eye on Alnylam's upcoming earnings report on October 29, 2026, as well as any further analyst ratings or target changes. Citigroup's reiterated Buy rating and adjusted target highlight a cautious but optimistic outlook for the company.
Related Filing Alerts
Source: Citigroup's rating change on $ALNY (Oct 14, 2026). Written by software, not financial advice. How we make alerts